

1 **Examination of the contribution of Nav1.7 to axonal propagation in**
2 **nociceptors**

3

4 George Goodwin¹, Sheridan McMurray², Edward B Stevens³, Franziska Denk¹ & Stephen B
5 McMahon¹

6 ¹Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London,
7 SE1 1UL, UK

8 ²Galvani Bioelectronics, Stevenage, SG1 2NY, UK

9 ³Lixion Ltd, Cambridge, CB22 5LD, UK

10 EBS was a consultant for MundiPharma

11

12 Corresponding author:

13 Dr George Goodwin

14 george.l.goodwin@kcl.ac.uk

15 Neurorestoration group

16 Wolfson Centre for Age-Related Diseases,

17 King's College London

18 London SE1 1U

19

20 **Abstract**

21 Nav1.7 is a promising drug target for the treatment of pain because individuals with Nav1.7 loss-of-
22 function mutations are insensitive to pain and do not have other serious neurological deficits.
23 However, current peripherally restricted Nav1.7 inhibitors have not performed well in clinical pain
24 trials, which may reflect a lack of understanding of the function of Nav1.7 in the transmission of
25 nociceptive information. Although numerous studies have reported that Nav1.7 has a moderate role
26 in peripheral transduction, the precise contribution of Nav1.7 to axonal propagation in nociceptors is
27 not clearly defined, particularly for afferents innervating deep structures.

28 In this study, we examined the contribution of Nav1.7 to axonal propagation in nociceptors utilising
29 sodium channel blockers in *in vivo* electrophysiological and calcium imaging recordings from L4 in
30 the mouse. Using the sodium channel blocker TTX (1-10 μ M) to inhibit Nav1.7 and other TTX-S
31 sodium channels along the sciatic nerve, we first showed that around 2/3^{rds} of nociceptive neurons
32 innervating the skin, but a lower proportion innervating the muscle (45%), are blocked by TTX. In
33 contrast, nearly all large-sized A-fibre cutaneous afferents (95-100%) were blocked by axonal TTX.
34 Characterisation of TTX resistant cutaneous nociceptors revealed that many were polymodal (57%)
35 and capsaicin sensitive (57%).

36 Next, we examined the role of Nav1.7 in axonal propagation in nociceptive neurons by applying the
37 selective channel blocker PF-05198007 (300nM-1 μ M) to the sciatic nerve between stimulating and
38 recording sites. 100-300nM PF-05198007 blocked propagation in 63% of C-fibre sensory neurons,
39 whereas similar concentrations did not affect propagation in rapidly conducting A-fibre neurons. We
40 conclude that Nav1.7 has an essential contribution to axonal propagation in only around 2/3^{rds} of
41 nociceptive C-fibre neurons, and a lower proportion (\leq 45%) of nociceptive neurons innervating
42 muscle.

43 **Introduction**

44 Non-selective pharmacological blockade of voltage gated sodium channels (Navs) with local
45 anaesthetics, such as lidocaine, at the peripheral or central component of sensory neurons is
46 effective in preventing the transmission of sensory input to the central nervous system (CNS) [15;
47 23]. In minor surgical procedures, complete pain-relief can be achieved in individuals by injecting
48 local anaesthetics around the appropriate peripheral nerve fibres, and even in extreme pathological
49 conditions, such as neuropathic pain caused by trauma or diabetes, similar results can be achieved
50 [19; 48]. However, as Navs are widely expressed throughout the peripheral and central nervous
51 systems [55], and are essential for electrical signalling in other tissue types, such as cardiac tissue

52 [36], the use of local anaesthetics outside of topical application (e.g. Lidoderm patches in
53 postherpetic neuralgia [16]) and acute nerve block for pain relief is limited.

54 There are 9 different Nav alpha subtypes (Nav1.1-1.9), five of which are expressed in adult
55 mammalian sensory neurons: the tetrodotoxin sensitive (TTX-S) subtypes Nav1.1, Nav1.6, Nav1.7
56 and the TTX resistant (TTX-R) subtypes Nav1.9 and Nav1.9 [55]. Nav1.1 and Nav1.6 are
57 predominantly expressed in large sized myelinated A-fibre neurons, which principally encode non-
58 nociceptive information, whereas Nav1.7-Nav1.9 are highly expressed in small unmyelinated C-fibre
59 neurons [55], which are nearly all classed as nociceptors [13]. In theory, selective inhibition of the
60 nociceptive sodium channel subtypes should be effective in providing analgesia in the absence of
61 extensive side-effects because their expression is mostly restricted to DRG neurons [55]. Nav1.7 is
62 the most promising nociceptive subtype to target with an inhibitor because individuals with Nav1.7
63 loss-of-function mutations are insensitive to somatic and visceral pain [9; 17]. Additionally, affected
64 individuals do not suffer from other sensory abnormalities (except anosmia) [51], and therefore
65 Nav1.7 inhibition might not be expected to produce serious side effects. Considering these findings
66 and observations, it is unsurprising that numerous Nav1.7 blockers are being developed as
67 analgesics. However, many of the small molecule inhibitors developed to date have not been further
68 progressed for the treatment of pain due to lack of efficacy in clinical trials [25].

69 Most of the Nav1.7 blockers that have failed in the clinic are peripherally restricted (poorly
70 penetrate the blood brain barrier (BBB)) which reduces the likelihood of off-target inhibition of
71 sodium channels in the brain. This means that peripherally restricted Nav1.7 inhibitors are only
72 capable of targeting channels located in the periphery, i.e. the peripheral terminals, axons or DRG,
73 and not the central terminals within the spinal cord, which are physically located across the blood-
74 spinal cord barrier. At the peripheral terminals of cutaneous afferents, pharmacological inhibition of
75 Nav1.7 reduces, but does not abolish, responses to noxious stimuli in around 2/3^{rds} of nociceptors
76 [20; 29], whereas inhibition at visceral afferent terminals is not reported to affect responses to
77 noxious stimulation [14; 20]. The consequences of Nav1.7 inhibition along peripheral axons are less
78 well defined because studies examining the role of the channel in axonal propagation are limited
79 due to the lack of selective blockers. Moreover, the available aryl sulphonamide Nav1.7 blockers are
80 only selective in certain species [1]. A previous pharmacological study in the rat reported that Nav1.7
81 is essential for propagation in all C-fibre neurons [41]. However, this is in contrast to numerous
82 studies reporting that propagation in a proportion (75-96%) of C-fibres is maintained when Nav1.7
83 (and other TTX-S channels) are blocked following axonal TTX application [24; 27; 37; 45; 52]. Studies
84 employing genetic knockdown of Nav1.7 also report that a proportion of C-fibres are capable of
85 propagation without the channel [21; 33].

86 To determine the proportion of nociceptive neurons dependent on Nav1.7 for axonal propagation,
87 we used in vivo electrophysiology and calcium imaging to measure evoked activity before and after
88 application of Nav blockers to peripheral nerve between stimulating and recording sites. Initially, we
89 sought to quantify the proportion of the nociceptive afferents innervating cutaneous and deep
90 structures that are dependent on TTX-S Navs for axonal propagation. Topical application of TTX
91 between stimulating and recording sites revealed a difference in the proportion of nociceptive
92 neurons dependent on TTX-S for propagation between skin and muscle innervating afferents.
93 Further experiments utilising a Nav1.7 selective blocker revealed that Nav1.7 is the major TTX-S
94 channel that is essential for axonal propagation in sensory C-fibre afferents.

95 **Materials and Methods**

96 **Animals**

97 Adult C57BL/6J mice (n = 30; Charles River, UK) weighing 24-30 g were used for in vivo imaging experiments.
98 Adult male CD1 mice (n = 23; Charles River, UK) weighing 30-45 g were used for electrophysiological
99 experiments. Mice were housed on a 12/12 h light/dark cycle with a maximum of 5 mice per cage, with
100 food and water available *ad libitum*. All experiments were performed in accordance with the United
101 Kingdom Home Office Animals (Scientific Procedures) Act (1986).

102 **Administration of AAV9-GCaMP6s**

103 We utilised the genetically encoded calcium Indicator GCaMP6s for imaging sensory neuron activity
104 [7]. GCaMP6s was delivered to sensory neurons via a adeno-associated viral (AAV) vector, which was
105 administered to mice pups at P3-P6 as previously described [50]. Briefly, groups of 3-4 mice were
106 separated from their mother and anaesthetised with 0.5-1% Isoflurane. 5 μ l of virus
107 AAV9.CAG.GCaMP6s.WPRE.SV40 (Addgene, USA) was injected intraplantar into the left hind paw
108 using a 10 μ l Hamilton syringe with a 34G needle attached. In experiments examining axonal
109 propagation in muscle afferents the virus was injected subcutaneously in the nape of neck. Following
110 the injection, pups were maintained on a heating pad until they woke up and were then returned to
111 their mother. Mice were separated from their mother after weaning and then were used for in vivo
112 imaging from 7-8 weeks after the injection.

113 **In vivo imaging of sensory neuron activity using GCaMP**

114 Mice were anesthetized using a combination of 1-1.25 g/kg 12.5% w/v urethane administered
115 intraperitoneally in addition to 0.5-1.5% isoflurane delivered via a nose cone. Body temperature was
116 maintained close to 37°C using a homeothermic heating mat with a rectal probe (FHC). An incision
117 was made in the skin on the back and the muscle overlying the L3, L4, and L5 DRG was removed.
118 Using fine-tipped rongeurs the bone surrounding the L4 DRG was carefully removed in a caudal-

119 rostral direction. Bleeding was prevented using gelfoam (Spongostan™; Ferrosan, Denmark) or bone
120 wax (Lukens). The DRG was washed and kept moist using 0.9% saline. The position of the mouse was
121 varied between prone and lateral recumbent to orient the DRG in a more horizontal plane. The
122 exposure was then stabilized at the neighbouring vertebrae using spinal clamps (Precision Systems
123 and Instrumentation) attached to a custom-made imaging stage. The DRG were covered with
124 silicone elastomer (World Precision Instruments, Ltd) to maintain a physiological environment. Prior
125 to imaging, animals received a subcutaneous injection of 0.25-ml sterile normal saline (0.9%) to keep
126 them hydrated. The mouse was then placed under the Eclipse Ni-E FN upright confocal/multiphoton
127 microscope (Nikon) and the microscope stage was diagonally orientated to optimise focus on the
128 DRG. The ambient temperature during imaging was kept at 32°C throughout. All images were
129 acquired using a 10× dry objective. A 488-nm Argon ion laser line was used to excite GCaMP6s and
130 the signal was collected at 500–550 nm. Time lapse recordings were taken with an in-plane
131 resolution of 512 × 512 pixels and a fully open pinhole for confocal image acquisition. All recordings
132 were acquired at 3.65 Hz. In some experiments, the skin was removed from the gastrocnemius
133 muscle. The exposed muscle belly was covered in gauze-soaked KREBS to prevent it from drying out.

134 **Electrical stimulation of the peripheral terminals**

135 In imaging experiments, the stimulating electrodes used consisted of an anode that was comprised
136 of 6 x 30G needles soldered to a single piece of wire and a cathode that was a single 30G needle. The
137 6 x 30G needles were inserted transcutaneously into the dorsal surface of the hind paw, while the
138 other needle was inserted into the skin at base of the ankle. A stimulator was used to deliver square
139 wave current pulses of 15mA and 15mS to activate the terminals of both A- and C-fibre neurons. 12
140 pulses (3Hz, 4s) were delivered at baseline and periodically post-drug application to assess axonal
141 propagation. In electrophysiological experiments, the peripheral terminals were stimulated with a
142 constant current stimulator (Digitimer, UK) connected to two stimulating pins inserted
143 transcutaneously into the dorsal hind paw. Square wave pulses of up to 450us, 450 mA were used to
144 recruit A-fibre neurons and pulses of up to 1ms, 2mA were used for C-fibres. For all experiments
145 involving electrical stimulation, 0.1Hz stimulation was applied throughout the recording to facilitate
146 PF007 binding [1].

147 **Thermal stimulation of the peripheral terminals**

148 A Peltier device (TSAll, Medoc) with a 16 x 16 mm probe was carefully placed onto the plantar
149 surface of the hind paw ipsilateral to the DRG being imaged and was maintained in position using a
150 V-clamp. The temperature of the block was increased from a baseline temperature of 32°C to 50°C
151 at a rate of 8 °C/s and maintained for 2 seconds before returning to 32°C at the same rate. For cold

152 stimulation, the temperature of the Peltier was decreased to 0°C at a rate of 4 °C/s and maintained
153 for 2 seconds before returning to 32°C.

154 **Mechanical or chemical stimulation of the peripheral terminals**

155 Mechanically sensitive afferents were identified by 1) pinching using a pair of serrated forceps, 2)
156 brushing using a cotton bud or, 3) flexion and extension of the leg. At the end of some pharmacology
157 experiments capsaicin cream (10%) was gently applied to the plantar surface of the hind paw using a
158 cotton bud.

159 **Calcium imaging data analysis**

160 The image analysis pipeline Suite2P: (<https://github.com/MouseLand/suite2p>) [35] was utilised for
161 motion correction, automatic ROI detection and signal extraction. Further analysis was undertaken
162 with a combination of Microsoft Office Excel 2013, Matlab (2018a) and RStudio (Version 4.02). A
163 proportion (0.4) of the neuropil (the local background of each cell) was subtracted from the
164 fluorescent signal for each corresponding cell. To generate normalised data, a baseline period of
165 fluorescence was recorded for each ROI and changes from this baseline fluorescence were
166 calculated as $\Delta F/F$ and expressed as a percentage [8]. Cells were grouped into small to medium
167 ($\leq 750\mu\text{m}^2$) and Large ($>750\mu\text{m}^2$) sized neurons. A limitation of this technique is the accurate
168 determination of cell sizes. As we are imaging with the pinhole fully open across multiple planes,
169 cells that are located deeper in the tissue can appear larger due to dispersion of the fluorescence.
170 i.e. small cells located deeper in the tissue may appear medium sized. Therefore, we did not split the
171 size groups further into small and medium sized cells. For experiments examining axonal
172 propagation in neurons innervating the hind paw, neurons were tested for responses to heat, cold
173 and mechanical (pinch) stimuli (in that order). Stringent criteria were used for positive responses to
174 thermal and mechanical stimulation of the terminals. A positive response was taken if the average
175 signal during stimulation was 70% plus 4 SD above the relative baseline fluorescence i.e. the average
176 level of fluorescence immediately prior to the stimulation. For electrical stimulation, a positive
177 response was taken if the average signal during stimulation was at least 50% plus 2 SD above the
178 relative baseline. A neuron was classed as not conducting through the treatment site when the
179 average fluorescent signal fell below this threshold. In most instances, traces of non-conducting
180 neurons were double checked by examining raw Ca^{2+} traces. A positive response to capsaicin was
181 taken if the average fluorescence signal during the 5-minute post-capsaicin period was 50% plus 2
182 SD greater than the 2-minute baseline period. For experiments examining axonal propagation in
183 muscle afferents, only small to medium sized neurons responding at baseline to just muscle pinch
184 (denoted pinch only) and neurons responding to just hind paw brush (denoted brush only) that were

185 blocked by lidocaine at the end of the experiment were analysed. To facilitate drug block, neurons
186 were activated periodically by brush and pinch stimulation throughout the experiment (See Fig 2A).
187 At the end of each drug application period, the stimulation procedure was performed twice to
188 reduce likelihood of missing receptive fields activated at baseline.

189 **In vivo electrophysiology**

190 *In vivo* single-unit electrophysiological recordings from A- or C- fibre axons in the L4 dorsal root were
191 carried out in CD1 mice (n = 23), as previously described in the rat [3; 18]. Animals were anaesthetised
192 using a combination of 1-1.25 g/kg 12.5% w/v urethane intraperitoneally in addition to 0.5-1.5%
193 isoflurane delivered via a nose cone. The body temperature was maintained at 37°C using a rectal
194 thermistor probe connected to a heated pad (Harvard Apparatus, Kent, United Kingdom). A lumbar
195 laminectomy was performed from L2 to L5 to expose the spinal canal. The surrounding skin was
196 sutured to a metal ring to form a pool filled with warmed mineral oil. The dura mater was opened
197 and the left L4 dorsal root was cut close to the spinal cord. The cut end of the dorsal root was placed
198 onto a glass platform (4 × 2.5 mm).

199 Fine filaments were teased from the cut end of the dorsal root using finely sharpened forceps and
200 individually placed onto paired gold recording electrodes. Extracellular potentials were band-passed
201 filtered (10-5,000 Hz) and amplified (1k) and digitised using Spike 2 software (Cambridge Electronic
202 Designs, Cambridge, United Kingdom). Mechanical receptive fields were searched for and once a
203 field had been identified, needle electrodes were inserted into the skin at the receptive field
204 location. Electrical stimulation was applied as described above, and the number of fibres on each
205 filament was determined by slowly increasing the stimulus amplitude until the maximum number of
206 waveforms was elicited. To prevent a single electrical stimulus causing >1 action potential to be
207 produced from the same neuron, a cut-off amplitude of 450uA was used for A-fibres and 2mA for C-
208 fibres. Only clearly identifiable waveforms were studied (<8 fibre waveforms per filament). Neurons
209 were classified based on waveform shape and conduction velocity, which was determined from the
210 conduction distance and latency of individual waveforms. Conduction velocities above 16m/s were
211 considered A α / β -fibres, and below 1.2 m/s were considered C-fibres [56]. Neurons conducting in the
212 A δ -fibre were identified in some experiments, but we preferentially searched for C-fibres because
213 our primary aim was to compare the effects of Nav1.7 in this population. Once a small (2-7) group of
214 A- or C-fibre neurons with conduction velocities that were stable had been identified, the terminal
215 was stimulated at 0.1Hz and drugs were applied topically to the sciatic nerve. Neurons were
216 considered to not be conducting through the treatment site when they failed to produce an action
217 potential following 6 consecutive electrical stimulations, or, if at the end of the experiment, no
218 longer responded to mechanical stimulation of the receptive field.

219 ***In vivo* topical drug application**

220 The sciatic nerve was exposed at the level of the mid thigh and was freed from surrounding
221 connective tissue. A 2-3 mm portion of the nerve, located 1-2mm proximal to the trifurcation, was
222 carefully desheathed using the tip of a 30G insulin needle. To isolate the desheathed portion from
223 the surrounding tissue, the nerve was covered in 4% agar (MP Biomedicals) dissolved in 0.9% saline.
224 Once it had set, a well (~vol 25-30 μ L) was cut out around the desheathed portion and was filled with
225 warmed (37°C) Krebs solution. All drugs were warmed (37°C) before application, and the well was
226 periodically replaced with fresh drug solution throughout recordings. Each drug concentration was
227 applied sequentially for a duration of 20-30 minutes.

228 **Drugs and Chemicals**

229 All drugs were dissolved to make stock solutions and then frozen at -20°C until their day of use. TTX
230 (Acros Organics, Fisher Scientific) and 4,9-Anhydrotetrodotoxin (Tocris, UK) were dissolved to 1mM
231 in 0.2 mM citric acid (pH 4.8). PF-05198007 (a gift from Dr S McMurray [1]), was dissolved in DMSO
232 to 10mM. Lidocaine hydrochloride (Sigma, UK) was dissolved in 0.9% w/v sodium chloride to a
233 concentration of 74mM (2% w/v). Drugs were diluted down to their final concentrations in either
234 freshly carbogenated (95% O₂ 5% CO₂) Krebs solution (In mM: NaCl, 118; KCl, 4.7; NaHCO₃, 25;
235 KH₂PO₄, 1.2; MgSO₄, 1.2; glucose, 11; and CaCl₂, 2.5) adjusted to pH 7.4.

236 **Quantification and Statistical analysis**

237 Graphing and statistical analysis was undertaken with a combination of Microsoft Office Excel 2013
238 and GraphPad Prism (Version 8). All data sets were checked for normality using Kolmogorov-Smirnov
239 tests. Details of statistical tests and sample sizes are recorded in the appropriate figure legends.
240 Main effects from ANOVAs are expressed as an F-statistic and P-value within brackets. All data
241 plotted represent mean \pm SEM. Statistical differences between groups in *in vivo* imaging experiments
242 involving different drug groups, neuron sizes and doses were compared using a 3-way repeated
243 measures analysis of variance (ANOVA) with Sidak's post hoc comparisons. For imaging experiments
244 comparing drug effects on propagation in heat responsive nociceptors, statistical differences were
245 determined using a 2-way repeated measures ANOVA with Sidak's post hoc comparisons. For
246 imaging experiments involving muscle afferents, statistical differences between groups were
247 determined using a 2-way ANOVA with Tukey's post hoc comparison. The proportion of neurons
248 blocked by TTX in different stimuli response groups was compared using Chi-squared test. For
249 analysis of the *in vivo* electrophysiology data, conduction velocities were compared between models
250 using Kruskal-Wallis tests and the proportion of neurons blocked between drug groups was
251 compared using Fishers exact test.

252 Results

253 Axonal TTX application has differential effects on propagation depending on fibre type and 254 innervation territory

255 Electrical stimulation of the plantar surface of the hind paw activated neurons of all sizes
256 (small/medium neurons mean 71 (SEM 8.7) and large mean 22 (SEM 2.3); n = 11 animals; Fig 1A –
257 second panel). The total number of neurons recruited via electrical stimulation varied between
258 experiments (range of 58-157) and therefore the proportion of neurons responding to electrical
259 stimulation at each time point was averaged between animals. In a significant number of neurons,
260 TTX applied to the sciatic nerve between stimulating and recording sites blocked propagation; main
261 effect of TTX: $F(1, 7) = 339.6, P < 0.0001$; 3-Way ANOVA. Main effects of dose ($F(1, 7) = 8.58, P < 0.05$)
262 and neuron size ($F(1, 7) = 14.40, P < 0.01$) were also statistically significant, as were several
263 interactions, including between neuron size x TTX ($F(1, 7) = 24.84, P < 0.01$) – a result in line with
264 expectations, as TTX should preferentially block large sized neurons. Thus, 1 μ M TTX blocked 61.4%
265 (SEM 6.3) small to medium and 90.9% (SEM 4.2) large sized neurons, which was significantly
266 different to that of the control for each corresponding size group (mean block = 10.9%, SEM 1.8 and
267 3.0%, SEM 2.9; $p < 0.01$ & $p < 0.0001$ Sidak's post-hoc comparisons test for small to medium and large
268 sized neurons respectively; n = 4-5 mice group; Fig 1A- left & middle panels & 1B). Subsequent
269 application of 10 μ M TTX produced a small and non-significant increase in the number of axons
270 blocked (average of 71.0% (SEM 3.9) and 94.5% (SEM 1.9); $p = 0.41$ and $p = 0.85$ Sidak's post-hoc
271 comparisons compared to 1 μ M TTX for small to medium and large sized neurons respectively; Fig
272 1A - middle panel & 1B).

273 Not all small to medium sized DRG neurons are nociceptors and therefore we examined the effects
274 of TTX on propagation only in the neurons that responded to noxious heat stimulation at the
275 beginning of the experiment. TTX blocked propagation in a significant number of heat sensitive
276 nociceptors; main effect of TTX: $F(1, 5) [\text{Drug}] = 84.69, P < 0.001$; Repeated measures 2-Way ANOVA.
277 There was also a small but significant interaction between Dose x Drug group ($F(1, 5) = 15.93,$
278 $P < 0.05$). The average number of heat sensitive nociceptors blocked by TTX was 55.6% (SEM 5.6) at a
279 concentration of 1 μ M and 66.3% (SEM 4.2) at 10 μ M, which were both significantly different to
280 their corresponding time-matched controls (mean block = 9.1% , SEM 3.2 and 10.2%, SEM 2.4
281 following vehicle 1 & 2 respectively; both $p < 0.0001$ Sidak's post-hoc comparisons; n = 3-4 mice; Fig 1
282 C). The proportion of neurons not blocked by TTX were blocked by subsequent application of 1mM
283 lidocaine/ 1 μ M TTX to the sciatic nerve (100% block for all groups; n = 102-131 small to medium and
284 25-51 large neurons averaged from n = 2 mice; Fig 1A – experiments denoted by red dots in right
285 panel, 1B & C).

286 The proportion of nociceptive neurons innervating muscle afferents sensitive to axonal TTX
287 application was examined (See Fig 2A for experimental design). Presumptive muscle afferent
288 nociceptors were identified as small to medium sized neurons responding at baseline only to strong
289 muscle pinch, but not leg movement or hind paw brush (eliminating low threshold proprioceptive
290 and tactile afferents). TTX block in the presumptive muscle nociceptors was compared to non-
291 nociceptive large sized neurons that only responded to hind paw brush. The total number of neurons
292 activated varied between experiments (6-28 neurons activated by brush only, 12-30 neurons
293 activated by pinch only) and therefore the proportion of baseline responding neurons also
294 responding at each timepoint was averaged between animals. 1 μ M TTX caused a significant block of
295 propagation in both brush and pinch responsive groups (F [Drug] (1, 10) = 191.2 $P < 0.0001$; 2-way
296 ANOVA). There were also significant main effects between brush and pinch groups (F (1, 10) = 26.34
297 $P < 0.001$; 2-way ANOVA) and the interaction between drug and stimuli groups (F (1, 10) = 47.7,
298 $P < 0.0001$). 1 μ M TTX blocked 100% of brush afferents and 46.2% (SEM 6.0) pinch afferents, which
299 was significantly different to that of the control for each corresponding group (mean block = 7.4%,
300 SEM 3.7 and 15.3%, SEM 9.4; $n = 3-4$ mice/group; $p < 0.0001$ & $p < 0.01$ Tukey post hoc comparison for
301 brush and pinch afferents respectively; Fig 2 B-F, Movie 1).

302 **Tetrodotoxin resistant neurons innervating the hind paw are comprised of capsaicin sensitive**
303 **polymodal nociceptors**

304 Responses to heat, cold and mechanical stimuli were assessed prior to electrical stimulation in most
305 topical drug experiments and neurons were grouped according to their responses to different stimuli
306 (Fig 3A for summary of TTX experiments). The level of polymodality within a neuronal population
307 was assessed by determining the number of thermally responsive neurons also responding to
308 mechanical stimulation and the number of mechanically sensitive neurons also responding to
309 thermal stimulation (Supplementary table 1). Most temperature sensitive neurons also responded to
310 mechanical stimulation (67.1%, SEM 3.4 and 73.9%, SEM 3.5 for heat and cold groups respectively,
311 average from n = 13 mice; Supplementary Fig 1A). In contrast, a lower proportion of mechanically
312 sensitive neurons also responded to heat stimulation (mean = 32.4%, SEM 3.3) and very few also
313 responded to cold stimulation (mean = 5.2%, SEM 0.5; Supplementary Fig 1B). Levels of polymodality
314 were increased when assessed in neurons that responded to electrical stimulation (Supplementary
315 table 1).

316 The small to medium sized population not blocked by 1 μ M axonal TTX application contained a higher
317 proportion of polymodal neurons (56.8%, 75/132 responsive neurons) compared to the population
318 blocked by TTX (37.4%, 128/342 responsive neurons; $p < 0.001$, Chi-square test with Yates'
319 correction). The polymodal mechano-heat (M-H) group contained the highest proportion (40.1%,
320 71/177) of neurons that were not blocked by axonal TTX application, whereas the proportion of
321 mechano-cold (M-C) polymodal neurons was lower (20%, 2/10), but not significantly different ($p =$
322 0.35 vs M-H group, Chi-square test with Yates' correction; Fig 3B). All the polymodal heat-cold
323 neurons (6/6) were blocked by axonal TTX application. The proportion of unimodal neurons
324 responding to heat not blocked by axonal TTX was 37.8% (14/37), which was significantly different
325 compared to neurons responding to just mechanical (18.4%, 43/234; $p < 0.05$, Chi-square test with
326 Yates' correction; n = 6 mice). As nearly all large sized neurons were blocked by axonal TTX, no
327 comparisons were made within this population. To determine how many TTX-R neurons were TRPV1
328 positive, 10% capsaicin cream was applied to the corresponding area of the hind paw at the end of
329 the experiment. Application of capsaicin to the hind paw after 1-10 μ M TTX application to the nerve
330 caused a positive response in 56.9% (SEM 3.7 ; n = 3 mice; Fig 4C & D, Movie 2) of neurons that were
331 still conducting, which was greater than the number of responders following control (mean response
332 = 37.5%, SEM 3.0 ; n = 2 mice).

333 **Nav1.7 is the major TTX-S subtype in the proportion of nociceptors blocked by TTX**

334 *In vivo* recordings were made from 19 A-fibre (n=5 mice) and 62 C-fibre sensory neurons (n=18 mice)
335 that had conduction velocities which ranged from 19.9-40.3 m/s and 0.4-1.1 m/s respectively.

336 Conduction velocities of C-fibre neurons at baseline were not significantly different between the
337 three treatment groups (p= 0.26, Kruskal-Wallis test; Table 1). Mechanical receptive fields were
338 identified in the majority of A-fibre and C-fibre neurons identified electrically and were all located on
339 the plantar surface of the hind paw (Table 1). C-fibres with mechanical receptive fields only
340 responded to strong mechanical stimulation of the hind paw indicating that they were nociceptive.

341 We utilised the selective Nav1.7 blocker PF007 to examine how many nociceptors depend on Nav1.7
342 for propagation[1]. Preliminary dose range finding studies carried out in *ex vivo* compound action
343 potential (CAP) experiments found that 100-300nM PF007 applied between stimulating and
344 recording sites reduced the C-CAP but not the A-CAP (data not shown). In *in vivo* recordings, topical
345 application of 100nM-1 μ M PF-007 blocked conduction in 68.4% (13/19) of C-fibre neurons, whereas
346 vehicle application only blocked conduction in 8.3% (1/12; p<0.001 Fishers exact test; Fig 4 A & G).
347 Notably, the majority of C-fibre neurons blocked by PF007 were blocked at the most selective
348 concentration of PF007 (47.4% blocked following 100nM PF007; Fig 4B & C). Application of TTX
349 blocked conduction in a similar proportion (63.6%) of C-fibre neurons (14/22 blocked following
350 30nM-1 μ M; Fig 4A & D). Further application of 10 μ M TTX did not cause any additional increase the
351 proportion of fibres blocked (7/11 blocked following 30nM-10 μ M from 2 mice). Conduction slowing
352 typically preceded conduction block in C-fibre neurons following PF007 and TTX application, but not
353 vehicle (See examples in traces 4B, D & E). Application of 9mM Lidocaine blocked conduction in all C-
354 fibre neurons (18/18 from n=5 mice; Fig 4E & G). In comparison to C-fibres, the application of
355 300nM-1 μ M PF007 did not cause significant conduction block in A-fibre neurons (5.3% (1/19,
356 p<0.001 Fishers exact test compared to C-fibre; Fig 4A, F & G). All A-fibre neurons that were not
357 blocked by 300nM-1 μ M PF007 were blocked subsequently by application of 1 μ M TTX (14/14 from n
358 = 4 mice, Fig 4F & G).

359 Topical drug experiments with PF007 were repeated in GCaMP6s labelled mice to corroborate
360 electrophysiological findings. Surprisingly, in this preparation, application of PF007 to the sciatic
361 nerve between stimulating and recording sites did not exert a significant block on axonal
362 propagation ($F(1, 6)$ [Drug] = 0.58, $P=0.47$; 3-Way ANOVA), even when the concentration was
363 increased from 300 nM to 1 μ M ($F(1, 6)$ [Dose] = 2.55, $P=0.16$; 3-Way ANOVA). There was, however,
364 a significant main effect of neuron size (F [Size] (1, 6) = 19.44, $P<0.01$); the proportion of small to
365 medium sized neurons blocked at 300 nM (17.3%, SEM 4.1) and 1 μ M (21.1%, SEM 5.0) was
366 significantly greater than that of the large sized neurons at each corresponding dose (300 nM mean
367 block = 3.8%, SEM 2.5; 1 μ M mean block = 2.6%, SEM 2.6; $p<0.05$ and $p<0.01$ respectively, Sidak's
368 post-hoc comparison; $n = 4$ mice/group; Fig 5B). Similar to the % block in the small to medium sized
369 group, PF007 only blocked 17.9% (SEM 5.6) and 15.0% (SEM 5.5) of heat sensitive nociceptors at 300
370 nM and 1 μ M respectively, which was not significantly different to that of the control (mean block =
371 9.1%, SEM 3.2 and 10.2%, SEM 3.4 following vehicle 1 & 2 respectively; $F(1, 6)$ [Drug] = 1.16 $P=0.32$,
372 2-way ANOVA; Fig 5c).

373 The reason for the discrepancy in the proportion of nociceptors blocked by PF007 between
374 electrophysiological and calcium imaging experiments was not clear and therefore we decided to
375 use a different class of sodium channel blocker to further investigate this. Due to the limited
376 availability of Nav1.7 selective inhibitors in the mouse, we used 4,9 AH TTX, a selective blocker of
377 Nav1.1 and Nav1.6 [10; 39], and then blocked Nav1.7 in addition to these channels with TTX. The
378 population dependent on Nav1.7 for propagation can be estimated by subtracting the number of
379 neurons blocked after 4,9 AH TTX from the total blocked after subsequent TTX application. In pilot
380 dose range finding experiments, application of 1 μ M 4,9 AH TTX did not block propagation in small to
381 medium or large sized neurons (data not shown). In contrast, application of 3 μ M 4,9 AH TTX to the
382 sciatic nerve in-between stimulating and recording sites caused propagation failure in a significant
383 number of neurons ($F(1, 6)$ [Drug] = 77.12 $P=0.0001$). The main effects of Size ($F(1, 6) = 104.1$,
384 $P<0.0001$) and the interaction between Drug x Size ($F(1, 6) = 31.73$, $P<0.01$) were also significant. 4,9
385 AH TTX blocked conduction in 30.4% (SEM 5.7) of small to medium sized neurons, which was
386 greater, but not significantly different, to that of the time-matched control (mean block = 16.3%,
387 SEM 1.6; $p = 0.23$, Sidak's post-hoc comparison; $n = 4$ mice/group; Fig 6A & B). In contrast, 4,9 AH TTX
388 blocked (80.8%, SEM 2.6) large sized neurons, which was significantly different to the control (mean
389 block = 8.1%, SEM 2.7%, $p<0.0001$, Sidak's post-hoc comparison; Fig 6A & B, Movie 3). Subsequent
390 addition of 1 μ M TTX to the sciatic nerve further impacted axonal propagation. The main effect of
391 TTX addition was significant ($F(1, 6) = 1136$, $P<0.0001$), as were several interactions, including that
392 between Drug x Size x TTX addition ($F(1, 6) = 28.24$, $P<0.01$). The proportion of small to medium

393 neurons blocked by TTX increased to 73.5% (SEM 2.1) in the 4,9 AH TTX group and 70.3% (SEM 4.7)
394 in the vehicle group, which were both significantly different to the block produced previously (both
395 $p < 0.001$, Sidak's post-hoc comparison to block following 4,9 AH TTX or vehicle respectively; Fig 6 B).
396 In contrast, subsequent TTX application caused a significant increase in the % block in large sized
397 neurons in the vehicle group (mean block = 92.2%, SEM 2.7; $p < 0.0001$, Sidak's post-hoc comparison
398 to vehicle), but not the 4,9 AH TTX group (mean block = 98.8%, SEM 1.3; $p = 0.06$, Sidak's post-hoc
399 comparison to 4,9 AH TTX).

400 To examine the effects of blocking axonal Nav1.1 and Nav1.6 with 4,9 AH TTX in nociceptors, we
401 compared block in neurons that responded to noxious heat at the beginning of the experiment. In
402 contrast to the % block in small to medium sized neurons, a lower proportion of heat sensitive
403 nociceptors were blocked by 4,9 AH TTX (19.2%, SEM, 2.7), which was not significantly different to
404 the control (22.1%, SEM, 4.6; $F(1, 6)$ [Drug] = 0.08, $P = 0.77$, 2-WAY RM ANOVA). Subsequent addition
405 of TTX to the sciatic nerve had a significant effect on axonal propagation in heat sensitive
406 nociceptors ($F(1, 6)$ [TTX addition] = 137.8, $P < 0.0001$). The proportion of heat nociceptors blocked
407 by TTX increased to 59.6% (SEM 7.5) in the 4,9 AH TTX group and 60.5% (SEM 4.7) in the vehicle
408 group, which were both significantly different to the block produced previously (both $p < 0.001$,
409 Sidak's post-hoc comparison to block following 4,9 AH TTX or vehicle respectively; Fig 6 C).

410 Discussion

411 The proportion of C-fibre nociceptive neurons that depend on TTX-S Navs for axonal propagation
412 between the peripheral terminals and the DRG is reported to vary between studies [27; 37; 52], and
413 the contribution of Nav1.7 in particular has not been well defined. In this study, we utilised blockers
414 of Nav1.7 and other TTX-S channels to determine the precise contribution of Nav1.7 to axonal
415 propagation in nociceptors. Specifically, we have shown that only around 2/3 of nociceptors
416 innervating the skin, and less than half of those innervating the muscle, depend on TTX-S channels
417 for axonal propagation. A similar proportion of C-fibre nociceptors innervating the skin were blocked
418 using a selective inhibitor of Nav1.7, suggesting that this channel is the most essential for
419 propagation in the TTX-S population. Finally, our data has revealed that several polymodal
420 mechanoheat sensitive and TRPV1 expressing nociceptors innervating the skin are not dependent on
421 TTX-S Navs for propagation.

422 Around 2/3rds of nociceptive sensory neurons innervating the skin were blocked following axonal
423 application of TTX. While some previous studies examining TTX block of C-fibre CAPs have reported
424 up to 96% block of propagation along peripheral nerve [27; 37], it is possible that TTX block in these
425 studies was overestimated due to temporal dispersion of compound C-potentials. Moreover, these

426 studies examined C-fibres CAPS in peripheral nerves that contain sympathetic C-fibres, which
427 express Nav1.7 but not TTX-R channels [55], potentially confounding interpretation. Our
428 electrophysiological data revealed that, similar to TTX block, 2/3rds of C-fibre neurons were blocked
429 by axonal application of the Nav1.7 inhibitor PF007, which suggests that Nav1.7 is the TTX-S Nav
430 subtype essential for axonal propagation in this population of nociceptors. However, this does not
431 necessarily mean that Nav1.8, which is expressed in virtually all nociceptors [44; 55] and the major
432 contributor to the upstroke of the nociceptor action potential [38], has no role in propagation in this
433 population. For example, it is plausible that a block of Nav1.7 prevents the membrane reaching the
434 more depolarised threshold required for Nav1.8 activation.

435 It is not clear why PF007 failed to reproduce the same level of propagation block when examined in
436 our in vivo calcium imaging experiments. Mouse strain differences can be ruled out because a similar
437 proportion of C-fibre neurons were blocked by PF007 *ex vivo* in c57 mice compared to that found in
438 vivo in CD1 mice. Although different forms of electrical stimulation were used to assess axonal
439 propagation between experiments (imaging 4Hz vs 0.1-0.2Hz electrophysiology), higher frequency
440 stimulation would have been expected to facilitate block based on the state dependent
441 characteristics of PF007 [1].

442 Our electrophysiological and calcium imaging data revealed that ~1/3rd of nociceptors do not
443 depend on Nav1.7 or other TTX-S Navs for axonal propagation. This might explain why peripherally
444 restricted Nav1.7 inhibitors have not provided effective pain relief for chronic pain sufferers [25]. It
445 also suggests that there is a sizable population of neurons in which Nav1.7 and other TTX-S Navs are
446 not required for membrane depolarization in order to generate action potentials. As TTX-R neurons
447 were blocked by 1mM lidocaine, which is likely only selective for Navs [42; 46; 53], axonal
448 propagation in these neurons is dependent on the only other TTX-R Nav's expressed in sensory
449 neurons, Nav1.8 and Nav1.9. Indeed, a previous study identified Nav1.8 as the essential TTX-R
450 channel for propagation in this population [27]. We did not attempt to repeat this finding via
451 pharmacological Nav1.8 inhibition because the selectivity of most Nav1.8 compounds against Nav1.9
452 have not been tested due to the difficulty of expressing Nav1.9 channels in heterologous cell lines
453 [32], and other selective compounds, such as A-803467, are reported to lack efficacy in rodent
454 peripheral nerve preparations [27]. Nonetheless, our findings provide further indirect evidence in
455 support of Nav1.8 being the most critical Nav in the TTX-R population: we found that many TTX-R
456 neurons were TRPV1 peptidergic nociceptors, which are reported to lack Nav1.9 protein [12; 40].

457 It is reported that almost every nociceptor (~90%) expresses Nav1.8 protein [44]; this raises the
458 question of why some nociceptors, but not others, can propagate action potentials without other

459 Navs. Although the relatively depolarised threshold for Nav1.8 activation implies that other Navs are
460 usually required for action potential generation [38], reports demonstrate that some nociceptors
461 can generate [47] and propagate [27] signals with Nav1.8 channels alone, and this suggests that
462 Nav1.8 channels in these neurons could have unique gating properties to enable this. For instance,
463 they may have different post-translational modifications, or contain different beta subunits
464 combinations [22], which causes channels to activate at more hyperpolarised potentials, thereby
465 enabling function without other Navs. Alternatively, this population of neurons could have a more
466 depolarised resting membrane potential [11], which would negate the need for other threshold
467 Navs.

468 Our in vivo imaging data revealed that polymodality is common in sensory neurons innervating
469 glabrous skin, which is consistent with that previously found in our lab using this technique [8]. We
470 found that a higher proportion of small to medium sized M-H polymodal (~40%) were resistant to
471 axonal TTX compared to those only sensitive to mechanical stimuli, which likely reflects that some of
472 the neurons that are exclusively mechanosensitive are low threshold non-nociceptive neurons that
473 don't typically express TTX-R Navs. The proportion of polymodal neurons blocked by TTX along the
474 axon are similar to that reported previously when examining TTX-R transduction at the peripheral
475 terminals [47; 57]. Although it is tempting to speculate that the neurons resistant to TTX at the
476 terminal represent an overlapping population to those TTX-R along the axon, TTX is reported to
477 differentially block excitability at the terminals compared to the axon in jugular nociceptors, which
478 suggests the expression of TTX-R Navs may differ between neuronal compartments in some neurons
479 [28].

480 Most high threshold pinch responsive muscle afferents (55%) were not blocked by axonal TTX
481 application, whereas all low threshold cutaneous afferents were blocked by TTX, suggesting that full
482 block of TTX-S channels was achieved and that these propagating muscle afferents do not depend on
483 TTX-S Navs for propagation. Our data are consistent with previous reports that numerous high
484 threshold C-fibre nociceptors innervating the muscle do not require TTX-S Navs for action potential
485 propagation [31; 45]. The TTX-R muscle afferents were blocked by subsequent application of
486 lidocaine and therefore depend on TTX-R Navs for propagation. The hallmarks of chronic pain -
487 ectopic activity in nociceptors, spontaneous pain and central sensitisation within the spinal cord -
488 are more likely to arise following injury to the nerves and tissue of deep structures, compared to
489 those of the skin [26; 49; 54]. Therefore, preferential targeting of Nav subtypes expressed in muscle
490 afferents could be an effective strategy for blocking abnormal activity in these neurons. Given that
491 many muscle nociceptors do not depend on Nav1.7 for propagation, and that pain that is deep in

492 origin is a frequently reported in many chronic pain conditions [2; 4; 30; 34], it is unlikely that
493 peripherally restricted Nav1.7 inhibitors would provide effective pain relief in these individuals.

494 The TTX block of nearly all large sized neurons or those that responded to low threshold brush
495 suggests that large sized low threshold responsive afferents depend on TTX-S channels for axonal
496 propagation, which is consistent with previous findings [27; 37; 43; 52]. Our electrophysiological
497 data revealed that rapidly conducting A-fibre neurons (likely consistent with the large sized neurons
498 imaged) were not blocked by Nav1.7 inhibition, thereby suggesting that the channel does not make
499 a substantial contribution to propagation in these neurons. In contrast, nearly all the large sized
500 neurons were blocked with 4,9 AH TTX, a selective inhibitor of Nav1.1 and Nav1.6, suggesting that
501 either one or both channels support axonal propagation in this population. Nav1.6 is expressed at
502 nodes of Ranvier in large sized neurons [5; 6], and a previous pharmacological study identified it as
503 being the major contributor to axonal propagation in A-fibres [52].

504 **Conclusion**

505 Our data indicate that Nav1.7 has an essential role in axonal propagation between cutaneous
506 terminals and the DRG in only around 2/3rds of nociceptive neurons, whereas propagation in the
507 remaining third appears critically dependent on TTX-R Nav subtypes. In the majority of muscle
508 afferent nociceptors propagation is not critically dependent on Nav1.7 or other TTX-S channels.

509 **Acknowledgments**

510 This research was supported by a research grant from Mundipharma Research Limited, Cambridge,
511 UK. We thank Professor Thomas Sears and Dr Martyn Jones for helping to set up in vivo
512 electrophysiological experiments.

513 **Conflicts of interest**

514 The authors declare no conflicts of Interest

515 **Author contributions**

516 G.G. conceived, designed, and performed all the experiments, analysed data and wrote the
517 manuscript; S.M conceived experiments and provided conceptual input on the project. F.D. provided
518 conceptual input on the manuscript and corrected the manuscript; E.B.S provided conceptual input
519 on the project and corrected the manuscript; S.B.M. conceived, designed, supervised, and corrected
520 the manuscript.

521 **References**

- 522 [1] Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, Wilbrey A, Payne EC,
523 Gutteridge A, Cox PJ, Doyle R, Printzenhoff D, Lin Z, Marron BE, West C, Swain NA, Storer RI,
524 Stupple PA, Castle NA, Hounshell JA, Rivara M, Randall A, Dib-Hajj SD, Krafte D, Waxman SG,
525 Patel MK, Butt RP, Stevens EB. Subtype-Selective Small Molecule Inhibitors Reveal a
526 Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and
527 Presynaptic Release. *PLoS ONE* 2016;11(4):e0152405-e0152405.
- 528 [2] Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex
529 regional pain syndrome. *Neurology* 2001;57(12):2179-2184.
- 530 [3] Bove GM, Ransil BJ, Lin HC, Leem JG. Inflammation induces ectopic mechanical sensitivity in
531 axons of nociceptors innervating deep tissues. *J Neurophysiol* 2003;90(3):1949-1955.
- 532 [4] Bove GM, Zaheen A, Bajwa ZH. Subjective nature of lower limb radicular pain. *J Manipulative*
533 *Physiol Ther* 2005;28(1):12-14.
- 534 [5] Caldwell JH, Schaller KL, Lasher RS, Peles E, Levinson SR. Sodium channel Na(v)1.6 is localized at
535 nodes of ranvier, dendrites, and synapses. *Proc Natl Acad Sci U S A* 2000;97(10):5616-5620.
- 536 [6] Chen L, Huang J, Zhao P, Persson AK, Dib-Hajj FB, Cheng X, Tan A, Waxman SG, Dib-Hajj SD.
537 Conditional knockout of Nav1.6 in adult mice ameliorates neuropathic pain. *Sci Rep*
538 2018;8(1):3845.
- 539 [7] Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, Schreiter ER, Kerr RA, Orger MB,
540 Jayaraman V, Looger LL, Svoboda K, Kim DS. Ultrasensitive fluorescent proteins for imaging
541 neuronal activity. *Nature* 2013;499(7458):295-300.
- 542 [8] Chisholm KI, Khovanov N, Lopes DM, La Russa F, McMahan SB. Large Scale In Vivo Recording of
543 Sensory Neuron Activity with GCaMP6. *eneuro* 2018;5(1):ENEURO.0417-0417.
- 544 [9] Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J,
545 Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN,
546 Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience
547 pain. *Nature* 2006;444(7121):894-898.
- 548 [10] Denomme N, Lukowski AL, Hull JM, Jameson MB, Bouza AA, Narayan ARH, Isom LL. The voltage-
549 gated sodium channel inhibitor, 4,9-anhydrotetrodotoxin, blocks human Nav1.1 in addition
550 to Nav1.6. *Neurosci Lett* 2020;724:134853.
- 551 [11] Du X, Hao H, Gigout S, Huang D, Yang Y, Li L, Wang C, Sundt D, Jaffe DB, Zhang H, Gamper N.
552 Control of somatic membrane potential in nociceptive neurons and its implications for
553 peripheral nociceptive transmission. *Pain* 2014;155(11):2306-2322.
- 554 [12] Fang X, Djouhri L, McMullan S, Berry C, Waxman SG, Okuse K, Lawson SN. Intense isolectin-B4
555 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad
556 action potentials and high Nav1.9 expression. *J Neurosci* 2006;26(27):7281-7292.
- 557 [13] Fang X, McMullan S, Lawson SN, Djouhri L. Electrophysiological differences between nociceptive
558 and non-nociceptive dorsal root ganglion neurones in the rat in vivo. *J Physiol* 2005;565(Pt
559 3):927-943.
- 560 [14] Feng B, Zhu Y, La JH, Wills ZP, Gebhart GF. Experimental and computational evidence for an
561 essential role of Nav1.6 in spike initiation at stretch-sensitive colorectal afferent endings. *J*
562 *Neurophysiol* 2015;113(7):2618-2634.
- 563 [15] Fink BR, Cairns AM. Differential peripheral axon block with lidocaine: unit studies in the cervical
564 vagus nerve. *Anesthesiology* 1983;59(3):182-186.
- 565 [16] Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic
566 neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment
567 study. *Pain* 1999;80(3):533-538.
- 568 [17] Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young
569 C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB,
570 Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E,
571 Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR. Loss-of-


- 572 function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple
573 human populations. *Clin Genet* 2007;71(4):311-319.
- 574 [18] Goodwin G, Bove GM, Dayment B, Dilley A. Characterizing the Mechanical Properties of Ectopic
575 Axonal Receptive Fields in Inflamed Nerves and Following Axonal Transport Disruption.
576 *Neuroscience* 2020;429:10-22.
- 577 [19] Haroutounian S, Nikolajsen L, Bendtsen TF, Finnerup NB, Kristensen AD, Hasselstrom JB, Jensen
578 TS. Primary afferent input critical for maintaining spontaneous pain in peripheral
579 neuropathy. *Pain* 2014;155(7):1272-1279.
- 580 [20] Hockley JR, Gonzalez-Cano R, McMurray S, Tejada-Giraldez MA, McGuire C, Torres A, Wilbrey
581 AL, Cibert-Goton V, Nieto FR, Pitcher T, Knowles CH, Baeyens JM, Wood JN, Winchester WJ,
582 Bulmer DC, Cendan CM, McMurray G. Visceral and somatic pain modalities reveal Nav 1.7-
583 independent visceral nociceptive pathways. *J Physiol* 2017;595(8):2661-2679.
- 584 [21] Hoffmann T, Sharon O, Wittmann J, Carr RW, Vyshnevskaya A, Col R, Nassar MA, Reeh PW,
585 Weidner C. Nav1.7 and pain: contribution of peripheral nerves. *Pain* 2018;159(3):496-506.
- 586 [22] Hull JM, Isom LL. Voltage-gated sodium channel beta subunits: The power outside the pore in
587 brain development and disease. *Neuropharmacology* 2018;132:43-57.
- 588 [23] Jaffe RA, Rowe MA. Differential nerve block. Direct measurements on individual myelinated and
589 unmyelinated dorsal root axons. *Anesthesiology* 1996;84(6):1455-1464.
- 590 [24] Jeftinija S. The role of tetrodotoxin-resistant sodium channels of small primary afferent fibers.
591 *Brain Research* 1994;639(1):125-134.
- 592 [25] Kingwell K. Nav1.7 withholds its pain potential. *Nat Rev Drug Discov* 2019.
- 593 [26] Kirillova I, Rausch VH, Tode J, Baron R, Jänig W. Mechano- and thermosensitivity of injured
594 muscle afferents. *Journal of Neurophysiology* 2011;105(5):2058-2073.
- 595 [27] Klein AH, Vyshnevskaya A, Hartke TV, De Col R, Mankowski JL, Turnquist B, Bosmans F, Reeh PW,
596 Schmelz M, Carr RW, Ringkamp M. Sodium Channel Nav1.8 Underlies TTX-Resistant Axonal
597 Action Potential Conduction in Somatosensory C-Fibers of Distal Cutaneous Nerves. *J*
598 *Neurosci* 2017;37(20):5204-5214.
- 599 [28] Kollarik M, Sun H, Herbstsomer RA, Ru F, Kocmalova M, Meeker SN, Udem BJ. Different role of
600 TTX-sensitive voltage-gated sodium channel (Nav 1) subtypes in action potential initiation
601 and conduction in vagal airway nociceptors. *J Physiol* 2018;596(8):1419-1432.
- 602 [29] Kornecook TJ, Yin R, Altmann S, Be X, Berry V, Ilch CP, Jarosh M, Johnson D, Lee JH, Lehto SG,
603 Ligutti J, Liu D, Luther J, Matson D, Ortuno D, Roberts J, Taborn K, Wang J, Weiss MM, Yu V,
604 Zhu DXD, Fremeau RT, Jr., Moyer BD. Pharmacologic Characterization of AMG8379, a Potent
605 and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel
606 Nav1.7. *J Pharmacol Exp Ther* 2017;362(1):146-160.
- 607 [30] Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tolle TR, Baron R. Fibromyalgia and
608 neuropathic pain--differences and similarities. A comparison of 3057 patients with diabetic
609 painful neuropathy and fibromyalgia. *BMC Neurol* 2011;11:55.
- 610 [31] Lambertz D, Hoheisel U, Mense S. Distribution of synaptic field potentials induced by TTX-
611 resistant skin and muscle afferents in rat spinal segments L4 and L5. *Neurosci Lett*
612 2006;409(1):14-18.
- 613 [32] Lin Z, Santos S, Padilla K, Printzenhoff D, Castle NA. Biophysical and Pharmacological
614 Characterization of Nav1.9 Voltage Dependent Sodium Channels Stably Expressed in HEK-
615 293 Cells. *PLoS ONE* 2016;11(8):e0161450.
- 616 [33] MacDonald DI, Sikandar S, Weiss J, Pyrski M, Luiz AP, Millet Q, Emery EC, Mancini F, Iannetti GD,
617 Alles SRA, Zhao J, Cox JJ, Brownstone RM, Zufall F, Wood JN. The mechanism of analgesia in
618 Nav1.7 null mutants. *bioRxiv* 2020:2020.2006.2001.127183.
- 619 [34] Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barre syndrome. *Neurology*
620 1997;48(2):328-331.

- 621 [35] Pachitariu M, Stringer C, Dipoppa M, Schröder S, Rossi LF, Dalgleish H, Carandini M, Harris KD.
622 Suite2p: beyond 10,000 neurons with standard two-photon microscopy. *bioRxiv*
623 2017:061507.
- 624 [36] Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA, Benndorf K, Saumarez RC, Trezise
625 AE, Huang CL, Vandenberg JI, Colledge WH, Grace AA. Slowed conduction and ventricular
626 tachycardia after targeted disruption of the cardiac sodium channel gene *Scn5a*. *Proc Natl*
627 *Acad Sci U S A* 2002;99(9):6210-6215.
- 628 [37] Pinto V, Derkach VA, Safronov BV. Role of TTX-sensitive and TTX-resistant sodium channels in
629 A-delta- and C-fiber conduction and synaptic transmission. *J Neurophysiol* 2008;99(2):617-
630 628.
- 631 [38] Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action
632 potential electrogenesis in DRG neurons. *J Neurophysiol* 2001;86(2):629-640.
- 633 [39] Rosker C, Lohberger B, Hofer D, Steinecker B, Quasthoff S, Schreibmayer W. The TTX metabolite
634 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium
635 channel. *Am J Physiol Cell Physiol* 2007;293(2):C783-789.
- 636 [40] Salvatierra J, Diaz-Bustamante M, Meixiong J, Tierney E, Dong X, Bosmans F. A disease mutation
637 reveals a role for NaV1.9 in acute itch. *J Clin Invest* 2018;128(12):5434-5447.
- 638 [41] Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB, Kaczorowski GJ,
639 Garcia ML, Koltzenburg M, Priest BT. ProTx-II, a selective inhibitor of NaV1.7 sodium
640 channels, blocks action potential propagation in nociceptors. *Mol Pharmacol*
641 2008;74(5):1476-1484.
- 642 [42] Scholz A, Vogel W. Tetrodotoxin-resistant action potentials in dorsal root ganglion neurons are
643 blocked by local anesthetics. *Pain* 2000;89(1):47-52.
- 644 [43] Schomburg ED, Steffens H, Mense S. Contribution of TTX-resistant C-fibres and A delta-fibres to
645 nociceptive flexor-reflex and non-flexor-reflex pathways in cats. *BritJAnaesth*
646 2000;37(4):277-287.
- 647 [44] Shields SD, Ahn HS, Yang Y, Han C, Seal RP, Wood JN, Waxman SG, Dib-Hajj SD. Nav1.8
648 expression is not restricted to nociceptors in mouse peripheral nervous system. *Pain*
649 2012;153(10):2017-2030.
- 650 [45] Steffens H, Eek B, Trudrung P, Mense S. Tetrodotoxin block of A-fibre afferents from skin and
651 muscle - a tool to study pure C-fibre effects in the spinal cord. *Pflugers Archiv - European*
652 *Journal of Physiology* 2003;445(5):607-613.
- 653 [46] Sugiyama K, Muteki T. Local anesthetics depress the calcium current of rat sensory neurons in
654 culture. *Anesthesiology* 1994;80(6):1369-1378.
- 655 [47] Touska F, Turnquist B, Vlachova V, Reeh PW, Leffler A, Zimmermann K. Heat-resistant action
656 potentials require TTX-resistant sodium channels NaV1.8 and NaV1.9. *J Gen Physiol*
657 2018;150(8):1125-1144.
- 658 [48] Vaso A, Adahan HM, Gjika A, Zahaj S, Zhurda T, Vyshka G, Devor M. Peripheral nervous system
659 origin of phantom limb pain. *Pain* 2014;155(7):1384-1391.
- 660 [49] Wall PD, Woolf CJ. Muscle but not cutaneous C-afferent input produces prolonged increases in
661 the excitability of the flexion reflex in the rat. *JPhysiolLond* 1984;356:443-458.
- 662 [50] Wang F, Bélanger E, Côté SL, Desrosiers P, Prescott SA, Côté DC, De Koninck Y. Sensory Afferents
663 Use Different Coding Strategies for Heat and Cold. *Cell Reports* 2018;23(7):2001-2013.
- 664 [51] Weiss J, Pyrski M, Jacobi E, Bufe B, Willnecker V, Schick B, Zizzari P, Gossage SJ, Greer CA,
665 Leinders-Zufall T, Woods CG, Wood JN, Zufall F. Loss-of-function mutations in sodium
666 channel Nav1.7 cause anosmia. *Nature* 2011;472(7342):186-190.
- 667 [52] Wilson MJ, Yoshikami D, Azam L, Gajewiak J, Olivera BM, Bulaj G, Zhang MM. mu-Conotoxins
668 that differentially block sodium channels NaV1.1 through 1.8 identify those responsible for
669 action potentials in sciatic nerve. *Proc Natl Acad Sci U S A* 2011;108(25):10302-10307.
- 670 [53] Xiong Z, Strichartz GR. Inhibition by local anesthetics of Ca²⁺ channels in rat anterior pituitary
671 cells. *European Journal of Pharmacology* 1998;363(1):81-90.

- 672 [54] Xu J, Brennan TJ. Guarding pain and spontaneous activity of nociceptors after skin versus skin
673 plus deep tissue incision. *Anesthesiology* 2010;112(1):153-164.
- 674 [55] Zeisel A, Hochgerner H, Lonnerberg P, Johnsson A, Memic F, van der Zwan J, Haring M, Braun E,
675 Borm LE, La Manno G, Codeluppi S, Furlan A, Lee K, Skene N, Harris KD, Hjerling-Leffler J,
676 Arenas E, Ernfors P, Marklund U, Linnarsson S. Molecular Architecture of the Mouse Nervous
677 System. *Cell* 2018;174(4):999-1014 e1022.
- 678 [56] Zimmermann K, Hein A, Hager U, Kaczmarek JS, Turnquist BP, Clapham DE, Reeh PW.
679 Phenotyping sensory nerve endings in vitro in the mouse. *Nat Protoc* 2009;4(2):174-196.
- 680 [57] Zimmermann K, Leffler A, Babes A, Cendan CM, Carr RW, Kobayashi J, Nau C, Wood JN, Reeh
681 PW. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures.
682 *Nature* 2007;447(7146):855-858.

683


684 **Figures and tables**



685

686 **Figure 1. Axonal TTX application blocks propagation in nearly all large sized neurons but only ~2/3**
 687 **of small to medium sized neurons.** Example images of L4 DRG cell bodies from in-vivo GCaMP6s
 688 time lapse recordings (A). Frames were extracted at baseline and at the peak of electrical stimulation
 689 at baseline and following each drug dose. The bar graphs show the proportion of neurons blocked
 690 following drug application to the nerve when neurons are grouped by size (B) and for neurons
 691 responding to noxious heat stimulation of the terminal (C). Each point represents the proportion of
 692 neurons blocked in an individual animal. 47-136 small to medium, 11-41 large neurons and 14-54
 693 heat responsive neurons were sampled between animals. Note that all sizes of neurons are activated
 694 by electrical stimulation of the paw at baseline. The electrically induced response was blocked in
 695 nearly all large sized cells following TTX application to the nerve, but only a proportion of small to
 696 medium sized neurons (middle panel). Small to medium sized neurons not blocked by TTX were
 697 blocked by lidocaine (right panel in A, grey bars in B & C). The red coloured dots denote the
 698 experiments in which lidocaine and TTX were applied to the nerve following 1 μ M TTX. Bar graphs
 699 represent mean \pm SEM. Scale bar = 50 μ M. 10x magnification. 3-way ANOVA for B) and RM 2-way
 700 ANOVA for C). ** $p < 0.01$, **** $p < 0.0001$ vs control Sidak's post hoc.


701



702


703 **Figure 2. Axonal TTX application blocks propagation in all brush responsive hind paw neurons but**
 704 **only 46% of pinch responsive small to medium sized muscle afferents.** Experimental schematic is
 705 shown in (A). Example calcium traces are presented in (B-D). Traces are shown for pinch responsive
 706 small to medium neurons (B,C) or brush responsive hind paw neurons (D,E) before and after TTX
 707 (B,D - blue) and Vehicle (C,E - black) application to the nerve. Note that only neurons responding at
 708 baseline to just muscle pinch or just brush that were blocked by lidocaine were analysed. The bar

709 graph shows the average proportion of neurons blocked after 25 mins of drug application for each
710 group (F). Between 6-28 brush and 12-30 pinch neurons were sampled between animals. Horizontal
711 bars represent stimulation periods. L – leg movement, B brush of plantar surface of hind paw, P –
712 pinch of exposed muscle belly. Bar graphs represent mean. 2-way ANOVA ** $p < 0.01$, **** $p < 0.0001$
713 vs control Sidak's post hoc. See also Movie 1.



714

715 **Figure 3. Small to medium sized neurons resistant to axonal TTX are comprised of polymodal and**
 716 **unimodal nociceptors and many are capsaicin sensitive.** Pie chart represents electrical responding
 717 small to medium sized neurons grouped according to their responses to different stimuli (A). Within
 718 each of these neuron groups, the neurons blocked by TTX (TTX-S), or not blocked by TTX (TTX-R) are
 719 expressed as a percentage of the total number of neurons within each group (B). 66-136 small to
 720 medium sized neurons pooled from n = 6 mice. A proportion of neurons responded to capsaicin
 721 following TTX application (C&D). Example images of L4 DRG cell bodies from in-vivo GCaMP6s time
 722 lapse recordings (C). Frames were extracted after 1 μ M TTX application before and 90s after
 723 application of capsaicin. Example calcium traces are shown in (D). Example Images were taken at 10x
 724 magnification, scalebar = 50 μ m. See also Movie 2.




725

726


727

Figure 4. Topical application of PF007 blocked conduction in 2/3rds of C-fibre sensory neurons. 2/3^{ds} of C-fibre sensory neurons were blocked following topical application of PF007 or TTX (A –

728 middle panel, B, C & D), but not following vehicle (A-left panel, E). A-fibre neurons were not blocked
729 by PF007 but were blocked subsequently by application of TTX (A – right panel, F). Example traces of
730 C-fibre (B-E) and A-fibre (F) neurons on electrical stimulation of the hind paw. Conduction slowing
731 typically preceded block following application of PF007 (B & C) and TTX (D), whereas slowing was not
732 apparent following vehicle application (E) or following PF007 application to A-fibre neurons (F). (G)
733 Summary of electrophysiology data *** $p < 0.001$ Fishers exact test. n=5-6 mice/group. Number of
734 neurons in each group shown in (A). Note that the final application of vehicle was not possible in n=2
735 mice due to technical issues.



737 **Figure 5. Axonal PF007 application had minimal effects on propagation when assessed in mice via**
738 **GCaMP6s in vivo imaging.** Example images of L4 DRG cell bodies from in-vivo GCaMP6s time lapse
739 recordings (A). Frames were extracted at baseline and at the peak of electrical stimulation at
740 baseline and following each drug dose. The bar graphs show the proportion of neurons blocked
741 following drug application between stimulating and recording site when neurons are grouped by size
742 (B) and for neurons responding to noxious heat stimulation of the terminal (C). Each point
743 represents the proportion of neurons blocked in an individual animal. Between 31-124 small to
744 medium, 6-29 large neurons and 14-27 heat responsive neurons were sampled between animals.
745 The electrically induced response was blocked in few neurons after topical application of PF007 to
746 the sciatic nerve (A- right panel, B & C). Note that these data were collected at the same time as the
747 TTX data in Fig.1 – the vehicle control results are therefore identical. Bar graphs represent mean \pm
748 SEM. Scale bar = 50µM. 10x magnification. 3-way ANOVA for B) and RM 2-way ANOVA for C). **
749 $p < 0.01$ vs control Sidak's post hoc test.



750
 751 **Figure 6. Axonal 4,9 AH TTX application blocked propagation in most large sized neurons but few**
 752 **small to medium sized neurons and very few nociceptors.** Example images of L4 DRG cell bodies
 753 from in-vivo GCaMP6s time lapse recordings (A). Frames were extracted at baseline and at the peak
 754 of electrical stimulation at baseline and following each drug dose. Note that nearly all large sized
 755 neurons (indicated by white arrows in the left panel) were blocked by 3 μ M 4,9 AH TTX, whilst many
 756 small to medium fibres are still conducting. The bar graphs show the proportion of neurons blocked
 757 following drug application between stimulating and recording site when neurons are grouped by size
 758 (B) and for neurons responding to noxious heat stimulation of the terminal (C). Each point
 759 represents the proportion of neurons blocked in an individual animal. Between 46-144 small to
 760 medium, 15-40 large neurons and 17-52 heat responsive neurons were sampled between animals.
 761 The shaded bars represent the proportion of neurons blocked following addition of 1 μ M TTX. D1-
 762 drug 1 (either 4,9 AH TTX or Vehicle). Bar graphs represent mean \pm SEM. Scale bar = 50 μ M. 10x
 763 magnification. 3-way ANOVA for B) and RM 2-way ANOVA for C). ** $p < 0.01$, *** $p < 0.001$, ****
 764 $p < 0.0001$ vs control Sidak's post hoc test. See also Movie 3.

	A-fibre	C-fibre		
	PF007/TTX	Vehicle/Lidocaine	PF007	TTX
CV (m/s), median (IQR)	21.72 (6.27)	0.54 (0.09)	0.52 (0.10)	0.55 (0.08)
No. of neurons (mice)	19 (5)	21 (6)	19 (6)	22 (6)
No. of mechanical receptive fields identified	13	12	11	12

765 **Table 1. Properties of A- and C-fibre neurons identified in experiments.**